Merkel Cell Carcinoma | A Pipeline Analysis Report 2018 | Technavio
LONDON--(BUSINESS WIRE)--Jul 6, 2018-- has announced its pipeline analysis report on the . The report includes a detailed analysis of the pipeline molecules under investigation within the defined data collection period to treat Merkel cell carcinoma.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180706005373/en/
Technavio has published a new report on the drug development pipeline for Merkel cell carcinoma, including a detailed study of the pipeline molecules. (Graphic: Business Wire)
This report presents a detailed analysis of the market, including regulatory framework, drug development strategies, recruitment strategies, and key companies that are expected to play an essential role in the growth of the market.
Merkel cell carcinoma - market overview
Merkel cell carcinoma (MCC) is a very rare type of skin cancer that develops when Merkel cells grow out of control. Merkel cells are present in the top layer of the skin and are involved in touch sensation. MCC was described for the first time as trabecular skin carcinoma in 1972. MCC is a rare but aggressive neuroendocrine skin cancer with frequent metastasis and death.
According to a senior analyst at Technavio for research on infectious and rare diseases , “MCC develops as a firm, rapidly enlarging, painless, and red-violet cutaneous nodule with a smooth surface. The site that gets affected by MCC most frequently is the head and neck region followed by the trunk and the limbs. MCC has been believed to be a cancer of immunogenic nature as it develops more often in patients with suppressed immunity because of human immunodeficiency virus infection and organ transplant in comparison with the people with adequate immunity.”
Merkel cell carcinoma: Segmentation analysis
This market research report segments the Merkel cell carcinoma market based on therapies employed (monotherapy, combination therapy, monotherapy/combination therapy, and unknown), RoA (oral, intravenous, intratumoral, parenteral, intralesional, intravenous + intratumoral/ intramuscular, and unknown), therapeutic modality (monoclonal antibody, small molecule, biological, oncolytic virus, and recombinant protein), targets for drugs under development (PD-L1, TLR, CD47, GITR, HDAC, IL-2, LAG-3, large-T cell antigen, MEK, mTOR, multitarget, NK cell, OX40, and unknown), and recruitment status (recruiting, active not recruiting, not yet recruiting, completed, terminated, and NA).
Monotherapy includes the use of a single drug to treat a disorder or a disease. In the current pipeline, around 38.89% of the molecules that are being investigated for the treatment of Merkel cell carcinoma are monotherapy.
In case of intravenous RoA, the drug substance is delivered directly into the vein. About 39% of the total molecules that are in the current pipeline are expected to be administered intravenously.
Technavio’s sample reports are free of charge and contain multiple sections of the report such as the market size and forecast, drivers, challenges, trends, and more.
Some of the key topics covered in the report include:
Scope of the Report
Drug Development LandscapeDrugs under development Indications coverage
Drug Development StrategiesTherapies employed RoA Therapeutic modality Geographical coverage
Recruitment StrategiesRecruitment status Gender Age Recruitment volume
Key CompaniesType of players Company overview
Discontinued or Dormant Molecules
is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.
With over 500 specialized analysts, Technavio’s report library consists of more than 10,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.
If you are interested in more information, please contact our media team at .
View source version on businesswire.com:https://www.businesswire.com/news/home/20180706005373/en/
CONTACT: Technavio Research
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
INDUSTRY KEYWORD: HEALTH ONCOLOGY PHARMACEUTICAL GENERAL HEALTH
SOURCE: Technavio Research
Copyright Business Wire 2018.
PUB: 07/06/2018 01:52 PM/DISC: 07/06/2018 01:51 PM